Using our anti-RAI2 polyclonal antibody in breast cancer research

Article: "Low RAI2 expression is a marker of poor prognosis in breast cancer"

Study analyzes RAI2 protein expression in invasive breast cancer tissues by IHC using our anti-RAI2 polyclonal antibody.

Low retinoic acid-induced 2 (RAI2) expression was considered a marker of poor prognosis in breast cancer as of today.

Now, using our anti-RAI2 polyclonal antibody (HPA051054), a new study analyzes RAI2 protein expression in invasive breast cancer tissues by IHC.

The results suggest that RAI2 has a role in the metastasis of breast cancer and that RAI2 expression could actually be used as a promising candidate biomarker of prognosis in breast cancer patients.

Read full article here.

Find out more about our Anti-RAI2 polyclonal antibody (HPA051054).